Mobocertinib NDA receives FDA Priority Review as treatment for EGFR Exon20 insertion+ metastatic NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mobocertinib (TAK-788) has received FDA Priority Review for the treatment of adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy. 

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
In This Issue